SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04）

Clinical trial NCT07633873 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07633873
Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small Cell Lung Cancer

Start date: 2026-06-02
Primary completion: 2027-09-30
Enrollment: 500

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.